Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupin To Draw On Efficiencies As Japan Pricing Pressures Build

Executive Summary

Pricing pressure in Japan is expected to weigh significantly on growth even in the generics segment, putting the focus on manufacturing and R&D efficiencies to sustain progress in this market, according to senior Lupin executives.

You may also be interested in...



Lupin Hit By US Settlement, Japan Injectables Selloff

Despite 10% revenue growth, Lupin ended up with a second-quarter loss from a one-time charge from settling a US lawsuit and the sale of its Japan injectables business. The firm is now counting on levothyroxine and secnidazole to carry it through the next few quarters, amid speculation that it might divest its Japanese subsidiary. 

Lupin Q2 Hit By US Settlement, Japan Injectables Selloff

Despite 10% revenue growth, Lupin ends up with a second-quarter loss from a one-time charge from settling a US lawsuit and the sale of its Japan injectables business. It's now counting on levothyroxine and secnidazole to carry it through the next few quarters, amid speculation that it might divest its Japanese subsidiary. 

Lupin Rationalizes Japan Operations, Sheds Injectables Business

Lupin sells Japanese injectables business, eight years after it made an acquisition in that segment there. The Indian firm now plans to concentrate on building a hybrid pharma model in the country.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125268

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel